Search PubMed⌕ Search

Biomedical subjects

Scott A Flanders

Publications and source records attributed to Scott A Flanders.

9 recordsLinked to original sources
PubMed2006

Effectiveness of ceftriaxone plus doxycycline in the treatment of patients hospitalized with community-acquired pneumonia.

BACKGROUND: Limited data exist on the effectiveness of ceftriaxone plus doxycycline in the treatment of patients hospitalized with community-acquired pneumonia (CAP). METHODS: We performed a retrospective cohort study of all adults hospitalized for pneumonia between January 1999 and July 2001 at an academic medical center. Outcomes were compared for patients with CAP treated with ceftriaxone plus doxycycline versus other appropriate initial empiric antibiotic therapies. Outcomes were adjusted with the use of a propensity score to account for differences in patient characteristics and illness severity between groups. RESULTS: A total of 216 patients were treated with ceftriaxone plus doxycycline and 125 received other appropriate initial empiric antibiotic therapies. After adjustment, use of ceftriaxone plus doxycycline was associated with reduced inpatient mortality (OR = 0.26, 95% CI: 0.08-0.81) and 30-day mortality (OR = 0.37, 95% CI: 0.17-0.81), but not with length of stay or readmission rates. Analysis of a subset of the sample that excluded patients admitted from nursing homes, patients admitted to the ICU, and patients diagnosed with aspiration also showed reduced inpatient mortality with the use of ceftriaxone plus doxycycline. CONCLUSIONS: The use of ceftriaxone plus doxycycline as an initial empiric therapy for patients hospitalized with CAP appears safe and effective, and its potential superiority should be evaluated prospectively.

Adult↗
PubMed2006

Community-acquired pneumonia: a practical approach to management for the hospitalist.

Community-acquired pneumonia (CAP) is common, and inpatient physicians should be familiar with the most current evidence about and guidelines for CAP management. Our conclusions and recommendations include: Streptococcus pneumoniae is the most common identified cause of CAP requiring hospitalization, whereas Legionella pneumophila is a common cause of severe CAP. The chest radiograph remains an essential initial test in the diagnosis of CAP and should be supplemented by blood cultures sampled prior to antibiotic therapy and sputum for gram stain and culture if a high-quality specimen can be rapidly processed. Once the diagnosis is made, the Pneumonia Severity Index (PSI) should be used to optimize the location of treatment and to provide prognostic information. Absent other mitigating factors, patients in PSI risk classes I, II, and III can safely be treated as outpatients. Hospitalized patients with CAP should be treated promptly with empiric antibiotics. Nonsevere pneumonia should be treated with a parenteral beta-lactam plus either doxycycline or a macrolide. Patients admitted to the intensive care unit should be treated with a beta-lactam plus either a macrolide or a fluoroquinolone as well as be evaluated for pseudomonal risk factors. Most patients with nonsevere CAP reach clinical stability in 2-3 days and should be considered for a switch to oral therapy and discharge shortly thereafter. Patients should receive pneumococcal vaccination, influenza vaccination, and tobacco cessation counseling prior to discharge if eligible. Multiple quality indicators are measured and publicly reported in the management of CAP, which provides hospitals with an opportunity to improve care processes and patient outcomes.

Community-Acquired Infections↗
PubMed2006

Nosocomial pneumonia: state of the science.

Nosocomial pneumonia is the leading cause of mortality due to hospital-acquired infections. A thorough understanding of the most recent developments in evaluating and managing nosocomial pneumonia is critical for infection control professionals and hospital epidemiologists, given the incidence and cost of this important patient safety problem. We review the evidence on pathogenesis, diagnosis, treatment, and prevention of both ventilator-associated and nonventilator-associated pneumonia. Key recommendations are then provided for diagnostic testing strategies, antibiotic selection, and treatment duration. We also summarize the most recent data on how to prevent hospital-acquired infection, in general, and nosocomial pneumonia, in particular.

Anti-Bacterial Agents↗
PubMed2006

Brief report: incidence, etiology, risk factors, and outcome of hospital-acquired fever: a systematic, evidence-based review.

OBJECTIVES: Temperature is universally measured in the hospitalized patient, but the literature on hospital-acquired fever has not been systematically reviewed. This systematic review is intended to provide clinicians with an overview of the incidence, etiology, and outcome of hospital-acquired fever. DATA SOURCES: We searched MEDLINE (1970 to 2005), EMBASE (1988 to 2004), and Web of Knowledge. References of all included articles were reviewed. Articles that focused on children, fever in the developing world, classic fever of unknown origin, or specialized patient populations were excluded. REVIEW METHODS: Articles were reviewed independently by 2 authors before inclusion; a third author acted as arbiter. RESULTS: Of over 1,000 studies reviewed, 7 met the criteria for inclusion. The incidence of hospital-acquired fever ranged from 2% to 17%. The etiology of fever was infection in 37% to 74%. Rates of antibiotic use for patients with a noninfectious cause of fever ranged from 29% to 55% for a mean duration of 6.6 to 9.6 days. Studies varied widely in their methodology and the patient population studied. CONCLUSIONS: Limited information is available to guide an evidence-based approach to hospital-acquired fever. We propose criteria to help standardize future studies of this important clinical situation.

Cohort Studies↗
PubMed2004

Performance of a bedside C-reactive protein test in the diagnosis of community-acquired pneumonia in adults with acute cough.

PURPOSE: To evaluate the performance of a rapid, bedside whole blood C-reactive protein test as a diagnostic test for pneumonia in adults. METHODS: We enrolled consecutive adults who presented with acute cough (duration < or =3 weeks). A fingerstick blood specimen for C-reactive protein level was obtained. Patients also provided information about demographic characteristics and symptoms. Physical examination findings, diagnoses, and treatments were abstracted from the medical record; illness duration and subsequent office visits were determined with follow-up telephone calls. A clinical prediction rule for pneumonia was calculated for each patient and compared with C-reactive protein levels. RESULTS: Twenty (12%) of the 168 patients in the study had radiographic evidence of pneumonia. Median C-reactive protein levels were significantly higher for patients with pneumonia than in the remaining patients (60 mg/L vs. 9 mg/L, P <0.0001). The area under the receiver operating characteristic (ROC) curve for C-reactive protein level as a predictor of pneumonia was 0.83. C-reactive protein level and the clinical prediction rule were independently associated with pneumonia, yielding a combined area under the ROC curve of 0.93. C-reactive protein level was not associated with hospitalization or resolution of symptoms. CONCLUSION: C-reactive protein levels could be a valuable addition to clinical prediction rules for pneumonia. A C-reactive protein level > or =100 mg/L might be a useful indication for chest radiography or empiric antibiotic therapy when the diagnosis of pneumonia is in doubt.

Adult↗
PubMed2004

Guidelines for community-acquired pneumonia: are they reflected in practice?

Community-acquired pneumonia (CAP) is common, costly, and clinically serious. Several national and international practice guidelines have been developed to promote more appropriate, cost-effective care for patients with CAP. This article compares and contrasts eight international practice guidelines for the management of CAP, describes the extent to which recommendations are reflected in practice, and proposes explanations for non-adherence to guidelines. We found consistency in recommendations across all the guidelines for the management of patients with CAP requiring intensive care. In this setting, all guidelines recommend chest radiography, sputum Gram stain and culture, blood cultures, testing for Legionella pneumophila, and timely administration of antibiotics active against both typical (i.e. Streptococcus pneumoniae, Hemophilus influenzae) and atypical organisms (i.e. Legionella spp., Mycoplasma pneumoniae, and Chlamydia pneumoniae). Recommendations for the management of the average inpatient with pneumonia were more variable, with the greatest differences between the North American and European guidelines. The North American guidelines (in contrast to European ones), recommended empiric treatment of typical and atypical organisms in all inpatients. There were also differences in policies regarding the necessity of chest radiography, sputum studies, and serologic testing. Some guidelines explicitly embrace the use of prediction rules to inform the decision to hospitalize, while others do not. Some of these admission decision algorithms focus on identifying low risk patients, while others are most concerned with high risk patients. There was also considerable variation in the specificity and operationalization of clinical criteria for switching from parenteral to oral antibiotics or judging appropriateness for discharge. Many recommendations for key management decisions tended to lack explicit, objective, and actionable criteria that could be easily implemented in real world practice. Review of the pneumonia literature revealed that physician performance of guideline-recommended best practices is often suboptimal. Administration of timely antibiotics (< or =8 hours of presentation) and use of first-line antibiotics occurred in 75-85% and 18-79% of cases, respectively. Collection of blood cultures within 24 hours of presentation and prior to administration of antibiotics was achieved in 69-83% and 63-82% of cases, respectively. Screening the eligibility of CAP patients for hospital-based pneumococcal and influenza vaccination occurred on average in 11 and 14% of hospitalizations, respectively, in the US. Lack of awareness of guidelines, conflicting advice among them, and lack of specific, objective, actionable recommendations most likely contribute to nonadherence to CAP guidelines. Increased attention to these factors will be needed if professional society practice guidelines are to fulfill their promise as tools for improving the quality and outcomes of care for patients with pneumonia.

Community-Acquired Infections↗